Instagram story viewer> @lonzagroup> Posts

Lonza

@lonzagroup

9.1K

followers

192

following

We are a pioneer in the CDMO industry, setting the pace with cutting-edge science and smart technology to make the medicines of tomorrow.

POSTS STORIES REELS TAGGED

100 million patients, every year.

That is the potential reach of the therapies we help bring to life at Lonza. Behind this number are our people – working side by side with our customers to turn their scientific breakthroughs into the medicines of tomorrow.

We are a community of big thinkers and bold doers. We focus on what matters, and together we make it happen. We are constantly pushing ourselves to make it better, never stopping until we make it right. This is a place of unique opportunity – to make what matters, on a global scale.

Discover how you could help make the medicines of tomorrow at lonza.com/careers.

#MakingWhatMatters #LifeAtLonza #CareersAtLonza by @lonzagroup

13

0

21 hours ago

Lonza is a place of unique opportunity.

It is a place you can make a real difference, working on therapies that reach patients around the world. Here, you will grow in remarkable locations, surrounded by people who bring different perspectives, experiences and expertise. You will be trusted to take responsibility, solve complex problems, and turn ideas into something real.

Lonza is a place where people come alive when they are making medicines that matter.

We are Lonza, and we are proud to be the makers of the medicines of tomorrow.

Find your unique opportunity at lonza.com/careers.

#APlaceOfUniqueOpportunity #CareersAtLonza by @lonzagroup

38

1

8 days ago

Imagine a place where the medicines people depend on are made – where scientific breakthroughs are taken from the lab and produced at scale.

Imagine a place of unique opportunity, where precision, care and responsibility matter at every step – and opportunities to grow are everywhere.

At Lonza, we partner with our customers to help create life-changing therapies that reach up to 100 million patients a year.

We are Lonza, and we are proud to be the makers of the medicines of tomorrow.

A career here is waiting to be made by you. Find your place to grow at lonza.com/careers.

#WeAreTheMakers #MedicinesOfTomorrow #LifeAtLonza by @lonzagroup

143

3

15 days ago

Today, we are pleased to welcome Hans Trees to Lonza as our Global Head of Communications.

Hans brings extensive international experience in corporate communications, reputation management, and stakeholder engagement, having held senior leadership roles across the life sciences industry. He will play a key role in further strengthening Lonza’s communications function and supporting the company’s strategic priorities.

We look forward to working with Hans as we continue to advance our purpose to turn our customers' breakthrough innovations into viable therapies and manufacture the medicines of tomorrow.

#Lonza #CDMO #Appointment #Leadership by @lonzagroup

44

3

2 months ago

Today, we announced our Half-Year Results 2026, delivering sales of CHF 3.4 billion with +16.0% CER sales growth. CORE EBITDA reached CHF 1.2 billion, resulting in a margin of 34.8%, while Free Cash Flow improved to CHF 0.4 billion. Based on our strong H1 performance, we upgraded our Full-Year 2026 CORE EBITDA margin outlook to 33–34%, while maintaining our CER sales growth guidance of 11–12%.

All three Business Platforms delivered double-digit CER sales growth, supported by sustained customer demand across technologies and geographies, continued momentum in strategic outsourcing activities and strong operational execution. We also expanded a strategic collaboration with a leading US biopharmaceutical company, reflecting the strength of our diversified business model and long-term customer partnerships.

In addition, we announced the further expansion of our commercial-scale ADC drug product capacity in Stein (CH), backed by a long-term customer commitment.

Read more about our Half-Year Results 2026 here: https://www.lonza.com/news/2026-07-22-06-30

#CDMO #Lonza #Growth #PharmaceuticalManufacturing #Biotech by @lonzagroup

100

0

3 months ago

What will it take to unlock the next wave of investment in extracellular vesicle (EV) therapeutics?

Lonza recently brought together investors, biotech leaders and industry experts in Boston to discuss the future of the field. From scientific and clinical progress to manufacturing readiness and investment trends, the conversations explored the opportunities and challenges shaping the next phase of EV therapeutics.

Thank you to everyone who joined us and contributed to an open and insightful discussion.

Looking to advance your extracellular vesicle program? Connect with our team to explore how Lonza can support your development and manufacturing journey.
https://www.lonza.com/contact by @lonzagroup

54

3

3 months ago

Today, we announced the expansion of our strategic collaboration with a leading US-based biopharmaceutical company, further strengthening a long-standing partnership. The agreement adds two biologics programs to be produced commercially, with the option for two more, and reflects the continued demand for Lonza’s integrated development and manufacturing solutions.

Through our global biologics network and advanced manufacturing technologies, we help customers accelerate complex programs with the flexibility, scalability, and quality needed to deliver innovative therapies to patients worldwide.

Read more: https://ow.ly/PRxC50Zj0qQ

#Lonza #CDMO #Biologics #Mammalian #IntegratedBiologics #PharmaceuticalManufacturing by @lonzagroup

75

4

4 months ago

We have announced plans to expand our payload-linker manufacturing capacity in Visp (CH), including new commercial-scale production capabilities, advanced purification infrastructure, and dedicated analytical and process development laboratories, further strengthening our integrated offering for antibody-drug conjugates (ADCs).

By investing in advanced capabilities for highly potent payload-linker synthesis and purification, we are enhancing our ability to support the growing demand for complex ADC therapies and enable flexible, scalable supply from development through to commercial manufacturing.

Read more: https://www.lonza.com/news/2026-06-30-07-00

#Lonza #CDMO #ADCs #HPAPI #Oncology #AdvancedSynthesis #PharmaceuticalManufacturing by @lonzagroup

84

1

4 months ago

We have announced a new licensing agreement with InduPro to advance next-generation antibody-drug conjugate (ADC) therapeutics supporting the advancement of highly targeted cancer therapies.

By combining our clinically validated bioconjugation platforms and linker-payload technologies with InduPro’s proprietary bispecific antibody capabilities, the collaboration aims to develop highly targeted ADCs designed to improve selectivity and therapeutic potential in complex cancers.

Read more: https://www.lonza.com/media-advisories/2026-06-22-14-00

#Lonza #CDMO #ADCs #Oncology #Bioconjugation #PharmaceuticalManufacturing by @lonzagroup

41

1

4 months ago

We have announced a new licensing agreement with Antharis Therapeutics to advance next-generation dual-payload ADCs targeting gastrointestinal cancers.

By combining Lonza’s clinically validated, site-specific ADC technologies with Antharis’ expertise in antibody engineering and target biology, the agreement aims to unlock dual-payload approaches designed to overcome resistance mechanisms beyond conventional single-warhead ADCs.

Read more: https://www.lonza.com/media-advisories/2026-06-15-15-00

#Lonza #CDMO #ADCs #DualPayload #Oncology #PharmaceuticalManufacturing by @lonzagroup

35

2

4 months ago

Speaking to Pharma’s Almanac, Behnam Ahmadian Baghbaderani, VP, Global Head of Commercial and Program Management for Specialized Modalities, shares his perspective on how increasing modality complexity is reshaping CDMO differentiation and specialization strategies.

He explains how the rapid rise of complex modalities (such as HPAPIs, ADCs, bispecifics, and cell and gene therapies) is driving a shift toward modality-specific expertise, supported by advanced analytics, robust process development, and tightly controlled GMP execution to address growing technical and regulatory challenges.

Read the full article here: https://ow.ly/LWp750Z9Lxh

#Lonza #CDMO #Innovation #Specialized Modalities by @lonzagroup

39

3

4 months ago

We have just announced a new licensing agreement with AmMax Bio, enabling access to Lonza's validated ADC platform to advance the next wave of targeted therapies for hematological cancers.

Through this collaboration, AmMax will leverage our linker-payload technologies to support the development of AMB-104, an investigational ADC designed to address resistance mechanisms in acute myeloid leukemia.

This agreement reinforces our role as a partner of choice for emerging biotechs, accelerating the development pathway from discovery to clinic while expanding the potential of precision oncology approaches.

Read more: https://www.lonza.com/media-advisories/2026-06-09-14-00

#Lonza #CDMO #ADCs #Bioconjugates #Oncology #PharmaceuticalManufacturing by @lonzagroup

56

1

4 months ago